Site Map

APOIMMUNE, INC. Incorporated:    June 2001 Contacts:    Steve Downey, President and CEO Description:    ApoImmune, Inc. is a biotechnology company committed to the development of powerful new therapeutics to treat chronic and acute life-threatening diseases and improve patients' quality of life. ApoImmune is founded on a broad-platform protein-based technology used for immunomodulation - that is - using one's own immune system to treat disease. ApoImmune's technology platform, licensed from the University of Louisville Research Foundation, is the result of more than a decade of research conducted by co-founder and Chief Scientific Officer Dr. Haval Shirwan. ApoImmune holds an exclusive worldwide license to the technology underlying this research. ApoImmune completed an institutional financing in 2006, receiving $500K in economic development incentives and continues to develop a lead vaccine product utilizing a $750K Phase I grant from NCI. The company has also been approved for a $1.8M SBIR grant in the current budget, (actual grant amount to be determined upon final SBIR budget). The ApoImmune team expects to receive another $1.2 million in NIH grants, including more $775K to advance a new vaccine approach and over $400K to advance the company's Cellular-Based Therapy for Type I Diabetes. ApoImmune continues to improve its intellectual property standing, having filed three additional patent applications. Phase I Clinical Trials for its lead product are anticipated to begin in 2009. Web Site:    http://www.apoimmune.com/ From the Mind to the Marketplace.

Copyright © 2008 MetaCyte Business Lab LLC. All rights reserved. | Privacy Policy | Site Map